Achieve Life Sciences, Inc. announced that it expects to receive $34.599898 million in funding

Published: 2026-04-16 11:28:19 ET ACHV

Published on 04/16/2026 at 11:28 am EDT

Achieve Life Sciences, Inc. announces that it has entered into a securities purchase agreement with new investors Frazier Life Sciences, TPG Life Sciences Innovations, venBio Partners, Paradigm BioCapital Advisors and Marshall Wace and also includes participation from both new and existing investors, including Coastlands Capital, Dialectic Capital, Janus Henderson Investors, LifeSci Venture Partners, Logos Capital, Propel Bio Partners, Spruce Street Capital, Venrock Healthcare Capital Partners, Vivo Capital and Wellington Management. to issue 49,418,069 shares of common stock at a price of $3.635 per share for gross proceeds of $179,634,680.815, 100,500 pre-funded warrants at a purchase price of $3.634 per pre-funded warrant for proceeds of $365,217 and warrants to purchase up to 49,518,569 shares of common stock or pre-funded warrants, at a collective purchase price of $3.635 per share of common stock and accompanying warrant or, in lieu thereof, $3.634 per pre-funded warrant and accompanying warrant for aggregate proceeds of $179,999,897.815 on April 16, 2026. Each accompanying warrant will be exercisable at an exercise price of $3.51 per warrant share, or $3.509 per pre-funded warrant in lieu thereof.

The private placement is expected to close on April 17, 2026, subject to the satisfaction of customary closing conditions.